Onconetix (NASDAQ:ONCO) Major Shareholder Financial Lp Hrt Purchases 92,554 Shares

Onconetix, Inc. (NASDAQ:ONCO) major shareholder Financial Lp Hrt acquired 92,554 shares of Onconetix stock in a transaction that occurred on Wednesday, April 15th. The stock was purchased at an average cost of $0.76 per share, for a total transaction of $70,341.04. Following the completion of the transaction, the insider directly owned 197,052 shares in the company, valued at $149,759.52. This trade represents a 88.57% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their transactions with the SEC.

Financial Lp Hrt also recently made the following trade(s):

• On Tuesday, April 14th, Financial Lp Hrt acquired 74,350 shares of Onconetix stock. The stock was purchased at an average cost of $0.77 per share, for a total transaction of $57,249.50.

Onconetix Stock Down 0.9%

Onconetix stock traded down $0.01 during midday trading on Thursday, reaching $0.76. The stock had a trading volume of 1,640,803 shares, compared to its average volume of 4,878,667. Onconetix, Inc. has a 52-week low of $0.67 and a 52-week high of $74.29. The firm has a market cap of $498,300.00, a price-to-earnings ratio of 0.00 and a beta of 3.63. The company has a fifty day moving average of $3.07 and a 200 day moving average of $8.97.

Hedge Funds Weigh In On Onconetix

An institutional investor recently bought a new position in Onconetix stock. Pacific Capital Wealth Advisors Inc. bought a new position in shares of Onconetix, Inc. (NASDAQ:ONCO) during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm bought 13,000 shares of the company’s stock, valued at approximately $40,000. Pacific Capital Wealth Advisors Inc. owned 0.84% of Onconetix as of its most recent filing with the Securities and Exchange Commission (SEC). 23.89% of the stock is currently owned by hedge funds and other institutional investors.

Onconetix Company Profile

Onconetix, Inc, a biotechnology company, focuses on the research, development, and commercialization of solutions for men's health and oncology. It offers Entadfi, an FDA-approved, once daily pill that combines finasteride and tadalafil for the treatment of benign prostatic hyperplasia; and Proclarix, an in vitro protein-based blood diagnostic test for prostate cancer. The company was formerly known as Blue Water Biotech, Inc and changed its name to Onconetix, Inc in December 2023. Onconetix, Inc was incorporated in 2018 and is headquartered in Cincinnati, Ohio.